Controlling Antimicrobial Activity of Quinolones Using Visible/NIR Light-Activated BODIPY Photocages

  1. Contreras-García, Elena 1
  2. Lozano, Carmen 1
  3. García-Iriepa, Cristina 2
  4. Marazzi, Marco 2
  5. Winter, Arthur H. 3
  6. Torres, Carmen 1
  7. Sampedro, Diego 1
  1. 1 Universidad de La Rioja
    info

    Universidad de La Rioja

    Logroño, España

    ROR https://ror.org/0553yr311

  2. 2 Universidad de Alcalá
    info

    Universidad de Alcalá

    Alcalá de Henares, España

    ROR https://ror.org/04pmn0e78

  3. 3 Iowa State University
    info

    Iowa State University

    Ames, Estados Unidos

    ROR https://ror.org/04rswrd78

Show affiliations +
Journal:
Pharmaceutics

ISSN: 1999-4923

Year of publication: 2022

Volume: 14

Issue: 5

Pages: 1070

Type: Article

DOI: 10.3390/PHARMACEUTICS14051070 GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Pharmaceutics

Institutional repository: lock_openOpen access editor
bar_chart View metrics

Metrics

Cited by

  • Scopus Cited by: 3 (10-03-2023)
  • Web of Science Cited by: 3 (14-03-2023)

JCR (Journal Impact Factor)

(Indicator corresponding to the last year available on this portal, year 2021)
  • Year 2021
  • Journal Impact Factor: 6.525
  • Journal Impact Factor without self cites: 5.728
  • Article influence score: 0.879
  • Best Quartile: Q1
  • Area: PHARMACOLOGY & PHARMACY Quartile: Q1 Rank in area: 39/279 (Ranking edition: SCIE)

SCImago Journal Rank

(Indicator corresponding to the last year available on this portal, year 2021)
  • Year 2021
  • SJR Journal Impact: 0.922
  • Best Quartile: Q1
  • Area: Pharmaceutical Science Quartile: Q1 Rank in area: 21/189

Scopus CiteScore

(Indicator corresponding to the last year available on this portal, year 2021)
  • Year 2021
  • CiteScore of the Journal : 6.0
  • Area: Pharmaceutical Science Percentile: 74

Journal Citation Indicator (JCI)

(Indicator corresponding to the last year available on this portal, year 2021)
  • Year 2021
  • Journal Citation Indicator (JCI): 1.41
  • Best Quartile: Q1
  • Area: PHARMACOLOGY & PHARMACY Quartile: Q1 Rank in area: 30/361
€ View funding

Funding information

Funders

Bibliographic References

  • 10.1016/j.mib.2003.09.001
  • 10.1093/emph/eou024
  • 10.3390/molecules24173152
  • 10.1002/anie.201601931
  • 10.1002/ejoc.201900219
  • 10.1016/j.csbj.2019.11.007
  • 10.1021/acs.chemrev.8b00037
  • 10.1039/c2ra22363e
  • 10.1038/nchem.1750
  • 10.1002/ejoc.201700809
  • 10.1021/acs.chemrev.0c00663
  • 10.1016/j.addr.2021.01.009
  • 10.1021/cr300177k
  • 10.1083/jcb.140.1.171
  • 10.1038/sj.jid.5700093
  • Auvinen, (2012)
  • 10.1007/s10103-017-2317-4
  • 10.1016/j.bmcl.2006.06.030
  • 10.1021/acs.orglett.9b03624
  • 10.1021/acs.orglett.8b00100
  • 10.1039/C9CC01073D
  • 10.1021/jacs.8b04040
  • 10.1021/cb500525p
  • 10.1021/jacs.5b01297
  • 10.1039/C5CC00550G
  • 10.1021/acsabm.9b00259
  • 10.1039/D0CC02178D
  • 10.1093/jac/33.4.685
  • 10.1039/c0pp00195c
  • 10.1021/jacs.0c07139
  • 10.1128/AAC.00927-10
  • 10.1021/acs.joc.7b02729
  • (2003), Clin. Microbiol. Infect., 9, pp. 1
  • 10.1063/1.464913
  • 10.1103/PhysRevB.37.785
  • 10.1016/j.cplett.2004.06.011
  • 10.1021/cr9904009
  • Frisch, (2016)
  • 10.1039/b508541a
  • 10.1063/1.3484283
  • 10.1063/5.0004608